Ms. Kathryn Hayashi is President and CEO of TRIUMF Innovations, the business interface and commercialization arm, connecting TRIUMF, Canada’s particle accelerator centre, to the private sector via industry partnerships, licensing, and company creation.  TRIUMF Innovations is the co-lead with CPDC for the Canadian Medical Isotope Ecosystem (CMIE at www.cmie.ca), a new Strategic Innovation Fund project that will provide support and funding for growing Canada’s medical isotope sector, including a new CMIE Development Fund providing matching funds for new medical isotope innovation projects.

Ms. Hayashi is a Chartered Professional Accountant with more than 25 years of operational and strategic planning, finance and governance experience in not-for-profit organizations, public and private companies, start-ups, and commercialization accelerators/incubators.

Prior to TRIUMF Innovations, she was the Founding Chief Financial Officer of The Centre for Drug Research and Development (now adMare Bioinnovations), Canada’s national drug development and commercialization engine. In addition to her work establishing CDRD as a leader in pre-clinical translational research and commercialization, Ms. Hayashi presides as a Director and Audit Committee Chair for Michael Smith Health Research BC, Center for Commercialization and Cancer Immunotherapy at the Hôpital Maisonneuve-Rosemont, as well as Nimbus Synergies health tech fund and Discovery Parks technology incubator.